Table 4.

The HR for OS and PFS of LMR was pooled in subgroup analyses.

Subgroup	PFS				OS
	Study	HR [95%CI]	P value	I2	Study	HR [95%CI]	P value	I2
Country
China	3	0.58 (0.42,0.80)	P<0.001	0	3	0.61 (0.44,0.84)	0.003	0
Japan	1	0.96 (0.63,1.44)	0.845	NA	2	0.62 (0.38,1.02)	0.06	2.3
Sample size
<100	3	0.80 (0.60,1.07)	0.137	0	4	0.65 (0.47,0.90)	0.009	0
≥100	1	0.48 (0.29,0.78)	0.004	NA	1	0.52 (0.30,0.87)	0.014	NA
cut-off
≥3	2	0.49 (0.31,0.77)	0.002	0	3	0.50 (0.34,0.73)	P<0.001	0
<3	1	0.96 (0.63,1.44)	0.845	NA	1	0.77 (0.41,1.45)	0.42	NA
Follow-up
≤15	1	0.96 (0.63,1.44)	P<0.001	NA	2	0.62 (0.38,1.02)	0.06	2.3
>15	3	0.58 (0.42,0.80)	0.01	0	3	0.61(0.44,0.84)	0.003	0
Combined medication
Monotherapy	1	0.69 (0.44,1.08)	0.105	NA	2	0.64(0.43,0.97)	0.036	5.7
Combined therapy	3	0.71 (0.52,0.96)	0.126	57.1	3	0.59(0.41,0.85)	0.005	0

NA, Not Applicable.